| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 145,380 | 162,910 | 50,277 | 641,141 |
| Cost of revenue | 26,285 | 32,106 | 21,590 | 297,403 |
| Gross profit | 119,095 | 130,804 | 28,687 | 343,738 |
| Sales and marketing | 568,937 | 609,713 | 657,030 | 1,059,745 |
| General and administrative | 1,815,945 | 2,599,982 | 2,773,149 | 4,287,380 |
| Research and development | 4,480,678 | 4,687,459 | 4,870,019 | 4,880,315 |
| Depreciation and amortization | 267,383 | 291,414 | 280,445 | 351,235 |
| Total operating expenses | 7,132,943 | 8,188,568 | 8,580,643 | 10,578,675 |
| Loss from operations | -7,013,848 | -8,057,764 | -8,551,956 | -10,234,937 |
| Interest income, net | 13,194 | 12,158 | 13,601 | 263,335 |
| Realized gain on investments | 41,542 | 340,358 | 301,465 | 293,067 |
| Gain (loss) on disposition of assets | 4,000 | -9,004 | - | 3,513 |
| Gain (loss) on remeasurement of acquisition contingencies | -42,345 | 10,222 | - | -11,927 |
| Gain (loss) on equity method investment in joint venture | -55,959 | -13,760 | -1,444 | 12,683 |
| Gain on remeasurement of acquisition contingencies | - | - | 717,067 | - |
| Total other income (expense), net | -39,568 | 339,974 | 1,030,689 | 560,671 |
| Loss before income taxes | -7,053,416 | -7,717,790 | -7,521,267 | -9,674,266 |
| Income tax provision (benefit) | -1,166,593 | 12,327 | 12,004 | 22,189 |
| Net loss | -5,886,823 | -7,730,117 | -7,533,271 | -9,696,455 |
| Change in net unrealized gains (losses) on marketable securities, net of tax | -39,180 | -196,585 | -87,790 | 37,158 |
| Total other comprehensive income (loss) | -39,180 | -196,585 | -87,790 | 37,158 |
| Comprehensive loss | -5,926,003 | -7,926,702 | -7,621,061 | -9,659,297 |
| Basic | -0.16 | -0.23 | -0.24 | -0.32 |
| Basic | 37,890,923 | 33,108,399 | 32,048,953 | 30,494,206 |
| Diluted | -0.16 | -0.23 | -0.24 | -0.32 |
| Diluted | 37,890,923 | 33,108,399 | 32,048,953 | 30,494,206 |
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)